Recent Trends in Preparation of Poly(lactide-co-glycolide) Nanoparticles by Mixing Polymeric Organic Solution with Antisolvent

Table 1

Summary of processing conditions of o/w emulsion methods and major characteristics of PLGA nanoparticles.

Polymer (grade)	Solvent	Polymer (%)	Drug	D/P	Size (nm)	EE (%)	Reference
RG502H (0.16–0.24 dL/g)	DCM-DMSO	2.5	Amphotericin B	5.6	154	53	[14]
PLGA50 : 50 (40–75 kDa)	EA	2	Betamethasone-17-valerate	60	281	85	[15]
mPEG-PLGA (11 kDa)	DCM	2	Bufalin	5	164	82	[16]
RG502H (7–17 kDa)	DCM	5	β-Carotene	10	200∼800	1	[17]
PLGA75 : 25 (66–107 kDa)	DCM-acetone	0.1, 0.2	Celecoxib	25, 50	115∼436	31∼86	[18]
PLGA50 : 50 (10 kDa)	EA, PC	2	Coumarin-6	5	56∼306.6	41∼52	[19]
RG 50 : 50 H (40–75 kDa)	EA-DCM	2.5	Cucumin	10	162	77	[20]
RG 503 (n/a)	DCM	1.67	Cyclosporine A	20	220	90	[21]
PLGA50 : 50 (20–23 kDa)	DCM	1	Exemestane	n/a	169	64	[22]
PLGA50 : 50 (0.36∼037 dL/g)	DCM	3.3	Haloperidol	2.5∼5	524	23∼37	[23]
PLGA (n/a)	DCM	2.5∼5.0	Nimesulide	5∼10	212∼289	25∼100	[24]
RH503 (35–40 kDa)	EA	1	Paclitaxel	5	121	47	[25]
PLGA50 : 50 (25 kDa)	DCM	2.5	Paclitaxel	5	318	89	[26]
Antibody-PLGA50 : 50 (40 kDa)	Chloroform	3	Paclitaxel	20	319	91	[27]
R503H (0.32–0.44 dL/g)	DCM	5	Pirfenidone	50	225	31	[28]
PLGA50 : 50 (40–100 kDa)	DCM	1.25∼5.0	Praziquantel	10∼30	243∼360	82	[29]
mPEG-PLGA-PLL (n/a)	DCM-TFE	2	Rhodamine	1	198	90	[30]
PGA-PLGA (103.4 kDa)	PC	0.1	Saquinavir	10	120∼300	77	[31]
PLGA (n/a)	DCM	1	tPA	0.1	266∼320	66∼71	[32]
APRPG-PEG-PLA (n/a)	DCM	1	Fumagillin analog	5	130	66	[33]
PLGA85 : 15 (50–75 kDa)	DCM	12.5	Voriconazole	8∼100	207∼605	8∼63	[34]

Note: n/a, not available, not specified.
Polymer %, polymer concentration in an organic solvent; D/P, the weight ratio of drug to polymer; EE, drug encapsulation efficiency; DCM, dichloromethane; DMSO, dimethylsulfoxide; EA, ethyl acetate; TFE, trifluoroethanol; PC, propyl carbonate; tPA, tissue-type plasminogen activator.